Technology
Health
Pharmaceutical

Constellation Pharmaceuticals

$11.86
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.61 (5.42%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell CNST and other stocks, options, ETFs, and crypto commission-free!

About

Constellation Pharmaceuticals, Inc. Common Stock, also called Constellation Pharmaceuticals, is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. Read More The company utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product candidates include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA.

Employees
Headquarters
Cambridge, Massachusetts
Founded
2008
Market Cap
Price-Earnings Ratio
Dividend Yield
Average Volume
78.00K
High Today
$12.07
Low Today
$10.82
Open Price
$11.32
Volume
49.58K
52 Week High
$12.45
52 Week Low
$4.01

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
Medical
Therapy
Cancer Prevention
2018 IPO

News

Associated PressMar 14

Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2018 Financial Results

CAMBRIDGE, Mass., March 14, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its fourth-quarter and full-year 2018 financial results. “2019 is a year of data for Constellation, and our clinical programs are making significant progress and approaching important readouts,” said Jigar Raythatha, president and chief executive officer of Constellat...

55
Markets InsiderMar 6

Constellation Pharmaceuticals to Present at Upcoming Investor Conference

CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will present at the Oppenheimer & Co. Inc. Healthcare Conference in New York at 10:55 AM EDT on Wednesday, March 20. Live audio webcasts of these presentations and archives for replay will be available on the Investor Relations section of Co...

88
Guru FocusMar 4

Constellation Pharmaceuticals Appoints Jessica Christo as Chief Product Development Officer

CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. ( CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jessica Christo has been appointed Chief Product Development Officer. Ms. Christo brings to Constellation 25 years of product development experience in the biopharmaceutical industry. Most recently, she was Senior Vice President of Development Operations at Verastem ...

4

Earnings

-$9.96
-$6.88
-$3.79
-$0.71
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.74 per share
Actual
-$0.77 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.